126 related articles for article (PubMed ID: 38290173)
1. Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer.
Stevens S; Nindra U; Shahnam A; Wei J; Bray V; Pal A; Yip PY; Linton A; Blinman P; Nagrial A; Lee J; Boyer M; Kao S
J Geriatr Oncol; 2024 Mar; 15(2):101705. PubMed ID: 38290173
[TBL] [Abstract][Full Text] [Related]
2. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer.
Mooradian MJ; Cai L; Wang A; Qiao Y; Chander P; Whitaker RM
JAMA Netw Open; 2024 Apr; 7(4):e247542. PubMed ID: 38648057
[TBL] [Abstract][Full Text] [Related]
3. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C
J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540
[TBL] [Abstract][Full Text] [Related]
5. Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.
Nindra U; Shahnam A; Stevens S; Pal A; Nagrial A; Lee J; Yip PY; Adam T; Boyer M; Kao S; Bray V
Asia Pac J Clin Oncol; 2024 Feb; 20(1):16-24. PubMed ID: 36855021
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Bourhaba M; Quantin X; Tokito T; Mekhail T; Planchard D; Kim YC; Karapetis CS; Hiret S; Ostoros G; Kubota K; Gray JE; Paz-Ares L; de Castro Carpeño J; Wadsworth C; Melillo G; Jiang H; Huang Y; Dennis PA; Özgüroğlu M;
N Engl J Med; 2017 Nov; 377(20):1919-1929. PubMed ID: 28885881
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
Socinski MA; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Gray JE; Park K; Vincent M; Mann H; Newton M; Dennis PA; Antonia SJ
Clin Lung Cancer; 2021 Nov; 22(6):549-561. PubMed ID: 34294595
[TBL] [Abstract][Full Text] [Related]
8. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
Senan S; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Murakami S; Hui R; Faivre-Finn C; Paz-Ares L; Wu YL; Mann H; Dennis PA; Antonia SJ
ESMO Open; 2022 Apr; 7(2):100410. PubMed ID: 35247871
[TBL] [Abstract][Full Text] [Related]
9. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
[TBL] [Abstract][Full Text] [Related]
10. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N; Bar J; Garrido P; Garassino MC; McDonald F; Mornex F; Filippi AR; Smit HJM; Peters S; Field JK; Christoph DC; Sibille A; Fietkau R; Haakensen VD; Chouaid C; Markman B; Hiltermann TJN; Taus A; Sawyer W; Allen A; Chander P; Licour M; Solomon B
J Thorac Oncol; 2023 Feb; 18(2):181-193. PubMed ID: 36307040
[TBL] [Abstract][Full Text] [Related]
11. Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis.
Wang Y; Zhang T; Huang Y; Li W; Zhao J; Yang Y; Li C; Wang L; Bi N
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1154-1164. PubMed ID: 34963558
[TBL] [Abstract][Full Text] [Related]
12. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
[TBL] [Abstract][Full Text] [Related]
14. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
Faivre-Finn C; Spigel DR; Senan S; Langer C; Perez BA; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Hui R; Murakami S; Paz-Ares L; Broadhurst H; Wadsworth C; Dennis PA; Antonia SJ
Lung Cancer; 2021 Jan; 151():30-38. PubMed ID: 33285469
[TBL] [Abstract][Full Text] [Related]
15. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.
Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515
[TBL] [Abstract][Full Text] [Related]
16. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
Filippi AR; Dziadziuszko R; García Campelo MR; Paoli JB; Sawyer W; Díaz Pérez IE
Future Oncol; 2021 Dec; 17(34):4657-4663. PubMed ID: 34775804
[TBL] [Abstract][Full Text] [Related]
17. Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program.
Avrillon V; Daniel C; Boisselier P; Le Péchoux C; Chouaid C
Lung; 2022 Feb; 200(1):95-105. PubMed ID: 35141799
[TBL] [Abstract][Full Text] [Related]
18. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy - single institute experience.
Vrankar M; Stanic K; Jelercic S; Ciric E; Vodusek AL; But-Hadzic J
Radiol Oncol; 2021 Nov; 55(4):482-490. PubMed ID: 34821136
[TBL] [Abstract][Full Text] [Related]
20. Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study.
Horinouchi H; Atagi S; Oizumi S; Ohashi K; Kato T; Kozuki T; Seike M; Sone T; Sobue T; Tokito T; Harada H; Maeda T; Mio T; Shirosaka I; Hattori K; Shin E; Murakami H
Cancer Med; 2020 Sep; 9(18):6597-6608. PubMed ID: 32730697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]